iOrganBio

🚛 Delivering impactful therapies to patients takes more than good science. It requires a fully integrated chain of highly interconnected processes spanning pre-clinical development to manufacturing to quality assurance to the clinic. Join us for the Hope is Not a Workflow Symposium, a gathering focused on transforming collaboration into measurable manufacturing outcomes and clinical impact. Learn how aligned partnerships, shared standards, and practical execution can accelerate the path from discovery to scalable, commercial-ready therapies. iOrganBio is proud to sponsor this event, bringing together leading figures in biopharma to solve problems and overcome challenges. We extend our thanks to founding partners @pluristyx and Teknova for putting on this event. As an innovator in intelligent cell manufacturing, we’re redefining how human cells are engineered and reliably produced at scale for research and therapy. Together with our partners, we’re expanding access to life-changing therapies, developed with The Right Cells, Consistently, At Scale. 📋 Learn more and register for the event at hopeisnotaworkflow.com 📆 Mar 25, 2026 ⏰ 8:00am - 7:00pm 📍@ncbiotech 🌐 Learn more about iOB and our platform by visiting iorgan.bio #DrugDevelopment #Biomanufacturing #AdvancedTherapies #Biopharma

Artificial intelligence continues to transform the landscape of drug discovery, and the progress is only accelerating. In this clip from the Pharm Tech Drug Digest Podcast, CEO @DanielDelubac discusses how AI is being leveraged across the entirety of the drug development pipeline, from the design of drugs themselves to in silico modeling. New Approach Methodologies (NAMs) are a key part of this new wave of drug discovery. Using the CellDiscovery™ platform, iOrganBio is equipping partners with a powerful platform to discover, develop, and refine their cell and organoid models. Whether testing cell therapy efficacy, generating safety data using non-animal models, or customizing models for n-of-one drug discovery, we are providing biopharma with The Right Cells, Consistently, At Scale. 🎧 Listen to the whole Drug Digest episode at bit.ly/4loMPqz 🌐 Learn more about the iOB technology platform at iorgan.bio #AI #DrugDiscovery #DrugDevelopment #Biopharma #NAMs #Organoids

Coming up later this week, CEO @DanielDelubac joins pioneers across industry and academia at the 2026 Symposium on Applied AI in Biomanufacturing. Hosted by NC State BTEC, the conference will highlight key areas of innovation in the space including: ⚙️ Application of AI to improve manufacturing processes 📊 AI enhancement of analytical capabilities and release testing 🔎 Integration of AI in the quality oversight processes to improve decision-making 🚧 Challenges of AI integration, implementation and maintenance in a regulated environment @iOrganBio is proud to be a part of North Carolina’s thriving biotechnology and biomanufacturing ecosystems. By leveraging our automated transcriptomics platform to digitize cell state, we are able to unlock the potential of AI to build better biological models and manufacture cells and organoids with precision, all with unprecedented reliability and scale. 💻 Learn more about the event and join at btec.ncsu.edu/about/events/a… 📅 March 12, 2026 ⏰ 8:00am to 6:00pm 📍 Hybrid (Raleigh or Virtual) 🌐 Learn more about iOrganBio and our technology at iorgan.bio #AI #Biomanufacturing #Quality #ProcessDevelopment

We’re getting ready to take the stage for Demo Day at @indbio Investor Showcase. This exclusive investor event features early stage companies within the IndieBio portfolio working to advance human and planetary health. @iOrganBio is proud to be a part of an impressive line-up of ventures and to have the opportunity to share about our technology platform that is revolutionizing cell manufacturing. By digitizing cell states and leveraging the latest advancements in AI and automation, we’re expanding access to new cell and organoid types, accelerating process development of biological models, and empowering our partners’ impactful work that brings new therapies from the bench into the clinic. In the biopharma sector, the foundation of new therapies starts with cells, and at iOB we’re providing the means to manufacture The Right Cells, Consistently, At Scale. Event Details: 📆 March 11 2026 🏙️ Onsite event 2:00pm to 5:00pm 💻 Virtual event 5:00pm 📍 New York, NY 📝 To be a part of the action, register at sosv.com/announcing-ind… 🌐 To learn more about iOrganBio and our tech, visit iorgan.bio #deeptech #organoids #stemcells #venturecapital

🎙️ We have a new episode out! We chat with Drs. Shuibing Chen (@ChenShuibing) and Hans Clevers (@HansClevers) from the #ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development They discuss how stem cell–derived organoids and other new approach methodologies (#NAMs) can complement or replace animal models in preclinical research. 🔊 Listen now: bit.ly/46sLQQe

🎙️ iOB Co-Founder and Senior Scientific Advisor @ChenShuibing was recently featured on the @stemcellpodcast, the leading podcast dedicated to discussing the latest trends in stem cell research and innovation. Joining organoid pioneer @HansClevers, Dr. Chen discussed the latest developments in new approach methodologies (NAMs) adoption, and the need for improved reproducibility and sound predictivity to drive the development of human-relevant therapies. @iOrganBio is proud to be at the forefront of this revolution in biological modeling. 🔭 Using the CellDiscovery™ platform, we are accelerating process development and iteratively improving the bioequivalence, expanding access to new models and functional states, and increasing consistency and reliability of the next generation of cell and organoid models. 🎧 Listen to full episode at bit.ly/4rOtfGC 🌐 Learn more about iOrganBio at iorgan.bio #iPSC #organoids #NAMs #StemCells

💡 Innovation is vital across the entire landscape of drug development, including the regulatory space. We applaud the FDA as it releases further guidance for accelerating the development of individualized therapies in the rare disease field. The new guidance is intended to clear regulatory roadblocks, aligning it with modern advancements in biology and tech, and pave the way for faster clinical translation. Focusing on therapies with a specific genetic or cellular target, the new criteria applies to applications that have: 🔬 Identified the disease-causing abnormality. ⚙️ Demonstrated mechanism aimed at root cause biology 🗃️ Relied on well-characterized natural history data in untreated patients. 🎯 Confirmed successful target drugging or gene editing. 📈 Improvements in clinical outcomes if seeking traditional approvals iOrganBio is proud to provide custom cell and organoid models necessary for personalized therapeutic discovery and development. Using the CellDiscovery™ platform to create models from a patient’s own cells that are bioequivalent to the cells in their own body, we are helping power the n-of-1 therapeutic development revolution. 🦓 As Rare Disease Week comes to a close, we are looking forward to a future of expanded therapeutic access for the millions of patients affected by rare diseases, therapeutics that are only accessible with The Right Cells, Consistently, At Scale. 📝 Read the full FDA news release here fda.gov/news-events/pr… ✉️ To inquire about iOrganBio personalized cell and organoid models email partnering@iorgan.bio 🌐 To learn more about the iOrganBio technology platform visit iorgan.bio #RareDiseaseWeek #RareDiseases #PersonalizedMedicine #DrugDiscovery

Big news in the cell therapy space as @GileadSciences announces the acquisition of @arcellx, bringing two cell therapy innovators together under one roof. We congratulate everyone involved in this momentous deal! Within a pre-existing collaboration between Arcellx and @KitePharma Gilead subsidiary—the partners have already produced a successful BCMA-targeted CAR-T therapy, anitocabtagene autoleucel (anito-cel) that has demonstrated deep and durable responses with a predictable and manageable safety profile in multiple myeloma. Progress in the field of cell therapies is not accidental; it’s a result of relentless innovation and dedication to improved patient outcomes. At @iOrganBio , our mission is to expand access to these life changing therapies by transforming how we manufacture and use cells. With bioadaptive manufacturing, we are building better and more consistent models for our drug discovery and advanced therapy development partners, and using our platform technology to accelerate process development and cell product manufacturing. 📰 Read the full press release at ir.arcellx.com/news/news-deta… 🌐 To learn more about our technology platform at iorgan.bio

🎙️iOrganBio CEO @DanielDelubac was recently interviewed on the Drug Digest Podcast to discuss the future of biopharma discovery and the necessity of strong partnerships that address the key challenges of drug discovery and development spanning in vitro modeling, clinical translation, and scale-up. Talking with @PharmTechGroup Science Editor Feliza Mirasol, Delubac shared a wide range of insights into the drug discovery partnering ecosystem including: 🏭 How strategic outsourcing partnerships improve biopharma efficiency and scale 🚨 The ways in which partnerships reduce risks during early clinical development 🧬 How external expertise accelerates development for advanced and next gen therapies 🤝 What factors sponsors and drug developers consider when evaluating partners iOrganBio is proud to be part of a thriving ecosystem of biotechnology and biopharma partners who are driving forward progress on life changing advanced therapies. Cells are a central component of this mission of therapeutic innovation, and with our CellDiscovery™ and CellForge™ platforms, iOB is accelerating progress by providing The Right Cells, Consistently, At Scale. 🎧 Catch the whole episode at pharmtech.com/view/drug-dige… 🌐 Learn more about iOrganBio at iorgan.bio #DrugDiscovery #DrugDevelopment #Biopharma #NAMs

ICYMI: @iOrganBio was recently featured by one of our investors 2NDF in their 2025 Spotlight. This annual roundup highlights how scientific innovation and enterprising commercialization of the ventures in the 2NDF portfolio are combining in The Research Triangle to create world-changing technologies. Thank you to John Landers and Liam King, along with the rest of the 2NDF team for your continued support of iOB’s mission to revolutionize cell manufacturing, enabling the production of The Right Cells, Consistently, At Scale. 🔦 Check out the full Spotlight writeup by visiting 2ndf.org/the-spotlight-… 🌐 Learn more about iOB by visiting iorgan.bio

We at iOrganBio are happy to celebrate the recent passage of two landmark pieces of bipartisan legislation that will meaningfully move the needle for pediatric patients and the future of advanced therapeutics in the United States: 📗 The Mikaela Naylon Give Kids a Chance Act (H.R. 1262) and 📘 The Accelerating Kids’ Access to Care Act (H.R. 1509) Signed into law as part of the FY2026 appropriations package, these policies deliver real hope for children and families affected by rare diseases and complex medical conditions—populations that often rely on transformative innovations like cell and gene therapies. 🔬 Why this matters: ➡️ The Give Kids a Chance Act reauthorizes the Rare Pediatric Disease Priority Review Voucher (PRV) Program, a proven legislative incentive that accelerates the development of life-changing treatments for children with rare diseases by offering developers priority FDA review or the ability to transfer/sell the voucher. Since its inception, this program has catalyzed therapies for dozens of pediatric conditions—without extra cost to taxpayers. ➡️ The Accelerating Kids’ Access to Care Act addresses unnecessary delays in care by streamlining the process for out-of-state pediatric specialists to treat patients covered by Medicaid. This reform ensures that families don’t have to navigate red tape to access lifesaving expertise, whether it’s across town or across state lines. At iOrganBio, our mission is to scale access to next-generation cell technologies that make advanced therapies. These legislative wins reinforce the importance of policy that aligns with patient-centered innovation—ensuring that scientific breakthroughs can reach those who need them most. To all the advocates, clinicians, policymakers, patient groups, and industry peers who rallied behind these priorities—thank you. Your collaboration and persistence helped turn long-standing advocacy into law. 📄 Read more here: alliancerm.org/wp-content/upl… 🌐 Visit iorgan.bio to learn more about our mission and the technology behind it #RegenerativeMedicine #CGT #AdvancedTherapies #RareDisease

Join iOrganBio Director of Business and Corporate Development Ishaan Puranam at #SLAS2026 as world leaders in laboratory automation converge on Boston. Across pharma and biotechnology, drug discovery and development is limited by a lack of models that accurately addresses relevant biology in large part due to a bottleneck in the development and manufacturing of these models. Better iPSC-derived cell and organoid models are possible with iOrganBio’s CellDiscovery™ platform, leveraging single-cell transcriptomic data to digitize cell states and powerful AI to map differentiation trajectories of cells towards their final bioequivalent state. CellForge™ manufacturing uses these digitized cell states to monitor and actively guide cells and organoids along their differentiation pathway. This powerful feedback control system delivers a more consistent manufactured cell product, dynamically adapting to differences in raw materials, culture reagents, and environmental conditions. As wider adoption of #NAMs accelerates, it becomes increasingly important that models replicate the biology in question, and do so consistently. Using CellDiscovery and CellForge equips researchers with the tools they need to generate The Right Cells, Consistently, At Scale. To book a meeting with iOB at SLAS email partnering@iorgan.bio Learn more about the iOB platform by visiting iorgan.bio #SLAS2026 #LabAutomation #Organoids #AI #scRNAseq @SLAS_Org

Automation is an essential component of the platform that we are building at @iOrganBio, enabling us to accelerate discovery and control cell fate with greater precision. We are excited to be attending #SLAS2026 to network with other global leaders in laboratory automation. Across pharma and biotechnology, drug discovery and development is limited by a lack of models that accurately addresses relevant biology in large part due to a bottleneck in the development and manufacturing of these models. True bioequivalence in these is only achievable through iterative, parallelized, and automated design of experiment systems. The iOrganBio CellDiscovery™ platform is on the leading edge of this transformation, leveraging single-cell transcriptomic data to digitize cell state and powerful AI used to map differentiation trajectories of cells towards their final bioequivalent state. CellForge™ builds upon this computational primitive by using digitized cell states to monitor progression of cells throughout the entire differentiation process, and automating feedback control of culture conditions to bioadaptively manufacture cells and organoids with higher consistency and greater reliability. As wider adoption of #NAMs accelerates, having the right models with The Right Cells, Consistently, At Scale is more important than ever. Join us at SLAS 2026 by registering here: slas.org/2026 To book a meeting with iOB at SLAS email partnering@iorgan.bio Learn more about the iOB platform by visiting iorgan.bio #SLAS2026 #LabAutomation #Organoids #AI #scRNAseq

We are happy to welcome Karol Jarzabek as Chief Operating Officer at @iOrganBio. Karol is a seasoned operations leader with deep experience scaling biopharmaceutical and life science organizations. He brings a strong track record in operational transformation, manufacturing scale-up, and value creation across complex environments, including leadership roles spanning strategic finance, portfolio operations, M&A integration, and end-to-end supply chain execution. Most recently, he led value creation initiatives across a portfolio of life science companies, helping translate strategy into durable, measurable performance. To read more about Karol’s extensive background, visit businesswire.com/news/home/2026… As iOrganBio advances CellForge™, our AI-powered platform for reliable, scalable human cell manufacturing, Karol will lead operations, manufacturing, and regulatory alignment as we support more partners and expand the platform’s impact. We’re thrilled to have Karol’s leadership as we continue redefining how human cells are engineered and produced for research, drug development, and cell therapy. To learn more about the team and tech at iOB, visit iorgan.bio #Biotechnology #Biopharma #CellTherapy #AI

Catch @iOrganBio at the upcoming Advanced Therapies Week, February 9-12. We’re challenging the status quo of cell manufacturing with a platform that unlocks by treating cells as the complex and dynamic systems that we’ve always known them to be. Visit Booth MP2 in the Innovation Zone to explore the capabilities of our CellForge™ and CellDiscovery™ platform and discuss how iOrganBio can help partners to design, prototype, and build custom cell and organoid models with consistency and reliability. COO Karol Jarzabek will be representing iOB in San Diego, CA and his schedule is filling up quickly. Reach out to partnering@iorgan.bio to set up a meeting and learn how our technology can create for you The Right Cells, Consistently, At Scale. #AdvancedTherapies #AT26 #CellTherapy #Organoids @Phacilitate

Scenes from last week's Biotech Showcase where CEO @DanielDelubac gave a talk on how IORGANBIO’s technology platform is shaping the future of #NAM adoption by expanding access to new biological models, improving the consistency and reliability of models, and capturing patient diversity. By applying state-of-the-art laboratory automation to process development parallelization and leveraging semi-continuous scRNA-seq to power predictive AI modeling of cell state trajectory, iOrganBio is building models that are bioequivalent to the cells in our own bodies. To explore partnership opportunities email partnering@iorgan.bio #Organoids #NAMs #DrugDiscovery #DrugDevelopment #AI #JPM26

@drewvolpe Automating science? Sounds great to us!

It’s time to automate science. 🧬🦾

“The digitization process also allows us to iterate on models towards optimality, preempting failures at the clinical stage. This approach can save drug developers millions of wasted resources and money and ensure patients’ needs are met” Part 2 of Co-Founder and CEO Daniel Delubac’s interview with BioPharm International features a discussion on the potential impact of the iOrganBio technology platform on multiple points of the drug discovery value chain. Watch part 2 of the interview here: biopharminternational.com/view/transform… Catch part 1 of the interview here: biopharminternational.com/view/why-ai-na… Learn more about iOrganBio’s technology here: iorgan.bio #DrugDevelopment #NAMs #Organoids

Discover how @iOrganBio's CEO Daniel Delubac is revolutionizing drug development with AI-designed, human-derived models at #JPM2026. Are you ready to move beyond animal models? Learn more: hubs.ly/Q03-cJVs0 #JPMorganHealthcare #DrugDiscovery #CellEngineering #AIinBiotech